Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Watson, H. G
Right arrow Articles by Greaves, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: New anticoagulants: a story of promise and disappointment

Henry G Watson

School of Medicine, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK

Mike Greaves

Ward 16, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZD, UK, m.greaves{at}abdn.ac.uk

The anticoagulant drugs which are available currently — coumarins and heparins — are reasonably effective but are insufficiently specific and often inconvenient to manage. An improved understanding of the physiology of blood coagulation and its control mechanisms has led to the identification of target enzymes for novel, specific and potentially safer antithrombotics. These targets include the pivotal coagulation enzyme thrombin as well as other enzymes and co-factors within the tissue factor dependent coagulation pathway. In addition, analogues of physiological anticoagulants hold promise as therapeutic agents. It is likely that the range of drugs available for the management of thrombosis will expand over the next decade. There is the very real possibility of the introduction of orally active agents which may be used in fixed dosage regimens with no requirement for laboratory monitoring.

Key Words: anticoagulants • thrombosis.

References

  • Greinacher A. Lepirudin for the treatment of heparin induced thrombocytopenia. Heparin-induced thrombocytopenia (ed. By T.E Warkentin and A Greinacher) New York: Marcel Dekker, 2004;
  • 397-436. 2. Hirsh J., Heddle N., Kelton JG Treatment of heparin induced thrombocytopenia: a critical review. Archiv Intern Med 2004;164:361-9.[Abstract/Free Full Text]
  • Warkentin TE Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Practice and Research. Clin Haematol 2004;17:105-25.
  • Keeling DM, Davidson S., Watson HG The management of heparin induced thrombocytopenia. Brit J Haematol 2006;133:259-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Greinacher A., Eichler P., Lubenow R. et al. Heparin induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective studies to assess the value of parenteral treatment with lepirudin and its therapeutic APTT range. Blood 2000;96:846-51.[Abstract/Free Full Text]
  • Lubenow R., Eichler P., Lietz T. et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004;104:3072-77.[Abstract/Free Full Text]
  • Greinacher A., Lubenow R., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-5.[Abstract/Free Full Text]
  • Swan SK, Hursting MJ The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation 2001;103:1838-43.[Abstract/Free Full Text]
  • Lewis BE, Wallis DE, Leya F. et al. Argatroban anticoagulation in patients with heparin induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.[Abstract/Free Full Text]
  • Sheth SB, DiCicco RA, Hursting MJ et al. Interpreting the International Normalised Ratio (INR) in individuals receiving argatroban and warfarin. Thrombos Haemostas 2001;85:435-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Lincoff AM, Bittl JA, Harrington RA for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial. JAMA 2003; 289:853-63.[Abstract/Free Full Text]
  • Rajagopal V., Lincoff A., Michael MD et al. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart Journal 2006;152:149-54.[CrossRef]
  • Eriksson UG, Johansson S., Attman PO et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical Pharmacokinetics 2003;42:743-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heit JA, Colwell DW, Francis CW et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001;161:2215-21.[Abstract/Free Full Text]
  • Eriksson UG, Agnelli G., Cohen AT et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. Thrombos Haemostas 2003;89:288-96.[Web of Science][Medline] [Order article via Infotrieve]
  • Eriksson UG, Bergqvist D., Kalebo P. et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis CW, Berkowitz SD, Comp PC et al. Comparison of ximelagatran with warfarin for prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.[Abstract/Free Full Text]
  • Executive Steering Committee on Behalf of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003;362: 1691-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Petersen P., Grind M., Adler J. et al. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability and safety study. J Am Coll
  • Cardiol 2003;41:1445-51. 21. Eriksson H., Wahlander K., Gustafsson D. et al. A randomised controlled dose guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Thrombos Haemostas 2003;1:41-7.[CrossRef]
  • Schulman S., Wahlander K., Lundstrom T. et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.[Abstract/Free Full Text]
  • Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Thrombos Haemostas 2005; 3:103-11.[CrossRef]
  • Bernard GR, Vincent JL, Laterrer PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.[Abstract/Free Full Text]
  • Abraham E., Laterre PF, Garg R. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-41.[Abstract/Free Full Text]
  • Green C., Dinnes J., Takeda A. et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-126.[Medline] [Order article via Infotrieve]
  • Jo F., Adhikari NK, Meade MO Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Critical Care 2006;10:145.[CrossRef][Medline] [Order article via Infotrieve]
  • Kearon C., Comp P., Douketis J. et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. Thrombos Haemostas 2005:3:962-8.[CrossRef]
  • Yusuf S., Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76.[Abstract/Free Full Text]
  • Koopman MM, Buller HR Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Berkowitz SD, Marder VJ, Kosutic G., Baughman RA Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. Thrombos Haemostas 2003;1:1914-19.[CrossRef]
  • Alexander JH, Yang H., Becker RC et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. Thrombos Haemostas 2005;3:439-47.[CrossRef]
  • Eriksson BI, Borris L., Dahl OE et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after
  • total hip replacement. J Thromb Haemost 2006;4:121-8. 34. Lee AY, Vlasuk GP Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Inter Med 2003;254:313-21.[CrossRef]
  • Abraham E., Reinhart K., Svoboda P. et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomised, placebo-controlled, single-blind dose escalation study. Crit Care Med 2001;29:2081-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Abraham E., Reinhart K., Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomised controlled trial. JAMA 2003;290:238-47.[Abstract/Free Full Text]
  • Jilma B., Marsik C., Mayr F. et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002;72:403-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bauer KA New anticoagulants: anti IIa vs anti Xa- is one better? Thromb Thrombolysis 2006;21:67-72.[CrossRef]
  • Bates SM, Weitz JI Status of new anticoagulants. Brit J Haematol 2006;134:3-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Li T., Change CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med 2005; 352:2285-93.[Abstract/Free Full Text]
  • Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR A C1173T in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PloS Med 2005;2:e312.[CrossRef][Medline] [Order article via Infotrieve]
  • Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-19.[Abstract/Free Full Text]
  • Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 2, 51-58 (2007)
DOI: 10.1177/14746514070070020201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Watson, H. G
Right arrow Articles by Greaves, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?